Autologous hematopoietic stem cell transplantation
A utologous hematopoietic stem cell transplantation (autoHSCT) is used frequently to treat lymphomas and leukemias, childhood brain tumors, multiple myeloma, neuroblastoma, and autoimmune diseases. 1, 2 Autologous HSCT is also being evaluated through clinical trials for patients with ovarian and metastatic breast cancer. 3 Although autoHSCT may extend progression-free survival time, patients often experience interrelated symptoms such as pain, fatigue, nausea, and psychological distress 4, 5 and negative physiological sequelae including mucosal barrier injury. One such oral mucosal barrier injury is stomatitis. 6Y8 Stomatitis is an inflammation of the oral mucous membranes characterized by tissue erythema, edema, and atrophy, often progressing to ulceration. 9 Patients under going highrisk bone marrow transplantation (BMT) have reported stomatitis incidence rates of greater than 60% and 78% for ulcerative stomatitis. 10 A typical stomatitis time course 11 begins on BMT day +3, lasts for 9.5 days, and resolves by BMT day +12.7. Stomatitis-related oral pain may lead to dysphagia and related nutritional deficits and difficulty in speaking. 12 Life-threatening sepsis may result from pathogen entry through damaged mucosa into the peripheral blood circulation.
Sonis 13 described a 5-phase pathogenic model of stomatitisV initiation, message generation, signaling and amplification, ulceration, and healing. Initiation of DNA damage occurs almost immediately after chemotherapy and radiation therapy administration and is mediated through reactive oxygen species. Transcription factors activated include nuclear factor kappa B (NF-.B) that is capable of upregulating more than 200 genes including those coding for proinflammatory cytokines and adhesion molecules. This protein production leads to target cell injury, signaling, and amplification with the clinical outcome of mucosal injury. Bacteria colonizing oral ulcerations contain cell wall products that stimulate infiltrating macrophages to release additional cytokines. Stomatitis may be more severe in the presence of oral infection, in particular, herpes simplex virus. 14 Healing, which is characterized by epithelial proliferation and differentiation, reestablishment of local microbial flora, and decrease in oral pain, occurs in most patients by BMT day +15 in parallel with white blood cell count recovery.
Pain is a complex, subjective experience with physiological, sensory, affective, behavioral, cognitive, and sociocultural dimensions. 15 Stomatitis is the principal etiology of most pain reported during the 3-week post-HSCT period 16 and is often described as the most unforgettable ordeal of HSCT. 17 High incidence rates of oral pain up to 89% have been reported in patients who had BMT. 18 The sensory intensity of this oral pain ranges from mild discomfort to severe pain requiring opioid use. 19 Oral pain experienced by patients who had BMT has been described as increasing from BMT days +4 to +21, paralleling the trend for mucosal changes for 2 weeks post-BMT. 20 Conversely, patients have reported oral pain before and limited or no pain after BMT. 11 The affective dimension of pain in cancer populations is shown through positive associations between pain, anxiety, and depression. 21, 22 Elevated levels of depression have also been found in breast cancer patients. 23 The behavioral dimension of oral pain includes altered communication patterns 24 and use of medications, sleep, and relaxation. Oral pain is experienced cognitively within the context of the already traumatic HSCT experience. 21 Although evidence-based guidelines for prevention and treatment of cancer therapyYrelated stomatitis are available, 25 the optimal treatments for stomatitis and related oral pain are not established. The scientific literature generally presents only the overall intensity dimension of stomatitis-related oral pain. Assessment of the multiple dimensions of this oropharyngeal pain experience is necessary to elucidate this symptom more comprehensively.
The purpose of this study was to describe multiple dimensions of the stomatitis-related acute oropharyngeal pain experience in women with breast cancer undergoing autoHSCT. Specific aims were the following:
1. to describe the clinical characteristics of stomatitis; 2. to describe multiple dimensions of oral pain with and without swallowing; 3. to describe oral care regimens and analgesics used by participants; and 4. to examine the relationships between and among stomatitis severity, oral pain overall, sensory and affective dimensions intensity, state anxiety severity, and depression severity.
It was predicted that there would be significant positive relationships observed between oral pain and stomatitis severity, alteration in swallowing, state anxiety severity, and depression severity. Also hypothesized was that stomatitis severity, oral sensory pain intensity, and state anxiety severity would most accurately predict overall oral pain intensity. n 
Conceptual Framework
The relationships between and among the perception, evaluation, and response components of oral pain were explored within the Symptom Experience Dimension of the original Conceptual Model of Symptom Management (Figure 1 ). 26 This model, which has been tested subsequently in research studies and expanded, 27 views symptoms as subjective experiences reflecting biopsychosocial function, sensation, or cognitive changes. 26 The 3 interrelated dimensions of the model are symptom experience, symptom management strategies, and symptom management outcomes. The Symptom Experience Dimension involves the interaction of the patient's perception of, evaluation of, and response to a symptom. 26 Symptom perception refers to any perceived change in how a person usually feels or behaves as influenced by personal, environmental, and health illness variables. Symptom response includes feelings, thoughts, or behaviors related to actual or potential health problems. Symptom evaluation refers to selfjudgments regarding severity, cause, potential treatment effects, and symptom effects and includes symptom intensity, location, temporal nature, frequency, and associated pattern of disability. The goal of symptom management strategies is to stop or delay a negative outcome using professional and selfcare strategies through a dynamic patient-family-clinician partnership. 26 The Symptom Outcomes Dimension evaluates symptom outcomes through 10 multidimensional indicators, with symptom status viewed as central. 26 n Methods
Design and Subjects
A descriptive, correlational, cross-sectional design was used to examine research variables and hypothesized relationships. Eligibility criteria were as follows: (a) diagnosed with stage II, III, or IV breast cancer; (b) scheduled to receive conditioning chemotherapy and autoHSCT; (c) aged more than or equal to 18 years; and (d) able to read and comprehend English. The study was conducted at 2 urban, East Coast, National Cancer InstituteYdesignated comprehensive cancer centers with established HSCT programs. A convenience sample of 35 participants was recruited. Data were not collected for 3 participants on BMT day +7 because of critical illness, cancelled HSCT, or treatment site change. The resultant 32 participants were evenly divided between the 2 clinical sites.
Instruments
Instruments used were the Oral Assessment Guide (OAG), 28 the Oral Mucositis Index-20 (OMI-20), 29 the Painometer (POM), 30 the State-Trait Anxiety Inventory (STAI), 31 the Beck Depression Inventory (BDI), 32 and patient and clinical data forms.
ORAL ASSESSMENT GUIDE
The OAG 28 guided assessment of clinical and functional characteristics of oral cavity changes in 8 categoriesVvoice, swallowing, lips, tongue, saliva, mucous membranes, gingiva, and teeth/denturesVeach rated on 3 levels of descriptors: normal findings = 1, mild alterations = 2, and definitely compromised = 3. The overall OAG score is the sum of all subscale scores (range = 8Y24). Content-related and construct validity, clinical utility, and high, trained nurse-nurse interrater reliability (r = 0.912) have been reported. 28 The OAG has been used frequently to describe stomatitis incidence and severity in patients who had BMT. 19 The OAG took about 5 minutes to complete.
ORAL MUCOSITIS INDEX-20
The OMI-20, which is a downsized version of the Oral Mucositis Index (OMI), 20 was used to assess stomatitis characteristics. 29 The OMI-20 rates atrophy of the dorsal tongue; erythema of the labial mucosa (upper and lower), buccal mucosa (right and left), and tongue (dorsal, lateral, and ventral); and edema for the lateral tongue from 0 = ''normal'' to 3 = ''severe.'' Pseudomembrane/ulceration size for these same areas is measured from 0 = ''no ulceration/pseudomembrane'' to 3 = more than or equal to 2 cm 2 . The total possible score range is 0 to 60. Cronbach coefficient ! values have ranged from .90 to .96 for OMI-20 total, .92 to .95 for erythema, and .71 to .90 for ulceration. 29 Interrater reliability coefficients more than or equal to .80 were obtained for 17 of the 20 items. Test-retest reliability and construct-related and criterion-related evidence were demonstrated. The OMI-20 performed well in the HSCT population, with trained investigators using grading rules. 29 The Oral Mucositis Index Template was developed by G. D. Searle & Co (Skokie, Illinois) as a visual aid for scoring erythema severity and ulcer/pseudomembrane size (centimeter squared). Grading rules were used to standardize oral assessment ratings (DB McGuire, personal communication, 1999).
PAINOMETER
Multiple dimensions of oral pain were measured using the POM. 30 The hand-held POM uses a vertical 10-cm visual analogue scale (VAS) to rate overall pain intensity and 14 sensory and 11 affective pain word descriptors (WDS). 30 The VAS is anchored with the words no pain = 0 and worst possible pain = 10. The weighted scores assigned to the selected words are summed to give sensory (range = 0Y48) and affective (range = 0Y37) pain intensity scores. The total pain intensity score for the WDS is the sum of sensory plus affective scores (range = 0Y85). High correlations were found between initial and repeat VAS ratings (r = 0.88, P G .001). Test-retest reliability of the WDS ranged from 0.68 (P G .001) to 0.73 (P G .001) in rheumatoid arthritis. 30 Concurrent validity of the WDS was supported by correlations between the POM-WDS and the McGill Pain Questionnaire (r = 0.69, P G .001) and VAS (r = 0.85, P G .001). 30 Construct validity evidence for the POM was shown by significant decrease in pain scores for the WDS (t = 5.53, P G .001) and VAS (t = 6.18, P G .001) after the patients had received pain medication. 30 The POM assessment sheet captured oral pain intensity, worst intensity within the last 24 hours, sensory and affective WDS, length and duration of present episode, and locations.
STATE-TRAIT ANXIETY INVENTORY
The STAI measured anxiety through self-report state and trait anxiety scales. 31 Each scale consists of 20 statements that are rated by respondents for how they feel in general (trait) and at present (state) using a Likert-type scale anchored from 1 = ''not at all'' to 4 = ''very much so.'' The total score is the sum of all responses ranging from a minimum score of 20 to 39 (low anxiety), 40 to 59 (moderate anxiety), to a maximum of 60 to 80 (high anxiety). Spielberger et al 32 reported testretest reliability coefficients of .86 to .92 for the trait subscale and coefficients of .83 to .92 for the state subscale. 33 Construct validity has been demonstrated. 32 
BECK DEPRESSION INVENTORY
The BDI measured depression through participant self-report for how he/she has been feeling for the past week including today using a Likert-type scale rating each item 0 = ''no symptom'' to 3 = ''severe or persistent symptom presence.'' 34 Depression severity values are categorized as scores of 1 to 9 = minimal, 10 to 16 = mild, 17 to 29 = moderate, and 30 to 63 = severe. 35 The total possible score of 1 to 63 is obtained by summing the 21 responses. Concurrent validity for the BDI 36 has ranged between 0.61 and 0.66. Construct validity was shown through correlation with the Minnesota Multiphasic Personality Inventory-Depression subscale (0.75). 33 Internal reliability consistency was shown by a Cronbach coefficient ! of .84 in a sample of patients who had autoBMT. 5 Test-retest reliability in nonpsychiatric patients ranged from 0.60 to 0.90. 37 The BDI has been used in a wide variety of populations.
PATIENT DATA FORM AND CLINICAL DATA FORM
The patient data form recorded sociodemographic, cancer treatment data, and risk factors for stomatitis. The clinical data form recorded laboratory data, and chemotherapy, analgesic, antifungal, and antibiotic agents' administration.
n Procedures
The investigator received training in oral assessment techniques and use of the OMI and the OAG. Oral Mucositis Index training included calibrations and interrater reliability procedures using Kodachrome slides showing oral mucosal changes and corresponding scoring. Interrater reliability of more than or equal to 0.90 for the OMI and the OAG was obtained between the investigator and the dental consultant before data collection and during the study. The Institutional Review Boards of the Georgetown University Hospital, Washington, District of Columbia, and the Johns Hopkins Hospital, Baltimore, Maryland, approved the study. The investigator obtained written informed consent from all participants during a regularly scheduled clinic visit pre-HSCT. Sociodemographic data were collected immediately after informed consent was obtained. Clinical data were collected on BMT day +7 ± 24 hours in recognition of potential patient morbidity and were also abstracted from the medical record. The investigator performed all oral assessments and collected all data in the participant's room on the BMT unit as follows: POM, BDI, STAI, OAG, and OMI-20. The study otoscope (Welch Allyn, Skaneatles Falls, New York) provided an adequate intense white light illumination of the oral cavity. Infection control procedures required the use of the BMT unit flashlight for one participant. All data were maintained confidentially in a locked file cabinet located in the clinical research office space and were entered into a password-protected computer using Microsoft Access 38 version 97SR2 and were analyzed using STATISTICA 6.0 computer software. 39 n Statistical Analysis Descriptive statistics provided a demographic and clinical profile of participants. The conservative separate variance t test was used to test for a statistically significant difference between the 2 clinical sites for research variables at the 0.05 level. Partial and semipartial correlations were used to remove the effect of analgesic, anxiolytic, and antidepressant medications on the relationships observed between oral pain and stomatitis severity, alteration in swallowing, state anxiety severity, and depression severity. Although all eligible patients were recruited during the planned study period, the pool of potential participants was much lower than predicted. Therefore, the obtained power of a partial correlation was 45% (" = 55%) based on n = 31 and the preceding !, directionality, and effect size. 40 Stepwise regression yielded the most accurate predictors of overall oral pain intensity. The variables were entered in the regression equation in order of significance levels 39 using STATISTICA 6.0. The use of medications was not partialled out. However, the potential confounding effect of medications was considered in the interpretation of the regression results by estimating the percentage of variance accounted for by the medications. The obtained power was 36% (" = 64%) based on n = 31 and the same preceding regression characteristics and 58% (" = 42%) for one predictor. 38 Following the step analysis and the order of the entering predictors determination, increments of change in the proportion of variance accounted for as each variable was added to the regression (R 2 change) were tested for significance. The final regression equation with the " weights for the predictors, the multiple correlation coefficient, the proportion of the explained variance, and the standard deviation for the predictor variables to predict overall intensity of oral pain was measured by the standard of estimate based on the regression equation containing only statistically significant predictors.
n Results
Subject Characteristics
Sociodemographic profiles of the participants were similar between the 2 clinical sites and were representative of breast cancer autoHSCT populations seen previously at the sites. The sample was 100% women, with a mean age of 49 years (range = 32Y64 years), and primarily white (75%) ( Table 1 ). All 32 participants had received previous cancer surgery and adjuvant chemotherapy. Breast cancer stage, past treatment for breast cancer, source of stem cells, and autoHSCT protocol are presented in Table 2 . The t test computed between the 2 clinical sites for all research variables was not statistically significant at the 0.05 level.
Technical Adequacy of Instruments
Coefficient ! values were relatively high for the State Anxiety Scale and the Trait Anxiety Scale (.92), the BDI (.91), and the OMI (.83), and low for the OAG (.58).
Clinical Characteristics of Stomatitis
All participants had some degree of stomatitis as assessed by the OAG, and 31 participants (97%) had some severity of stomatitis as measured by the OMI (mean = 5.8). Stomatitis patterns (OMI) are presented in Table 3 . The OAG mean (SD) score was 13.0 (2.4). More than half (59%) of all participants reported a normal voice, and 6 (19%) stated that it was difficult or painful to talk (Table 4 ). Thirteen (41%) participants reported some alteration in swallowing. Dry cracked lips were evident in 20 (63%) participants. Only 8 (25%) participants had thick saliva. Reddened mucous membranes were seen in 24 (75%) participants, and gingiva was edematous in 12 (38%) participants.
Location, Intensity, Quality, and Duration of Oral Pain
Fifteen (47%) participants reported oral pain overall intensity mean (SD) VAS score = 1.3 (1.7) (range = 0Y5.4) ( Table 5 ). Five (16%) participants had present oral pain overall intensity VAS scores of more than 3. The worst oral pain overall intensity mean (SD) VAS rating in the past 24 hours was 2.0 (2.7) (range = 0Y10); 8 (25%) participants scored more than 3. The sensory plus affective pain mean (SD) score was 5.9 (9.3) (range = 0Y46). The most frequently chosen oral pain location was the throat (73.3%). Pain was also reported in the upper lips (20.0%), lower lips (26.6%), inside right cheek (46.6%), inside left cheek (46.6%), and tongue (73.3%). The most frequently chosen sensory words to describe oral pain were sore (66.7%), aching and dull (46.7%), and burning (26.7%). The most frequently chosen affective words used to describe oral pain were annoying (80.0%), nagging (53.3%), and troublesome (83.3%). Continuous oral pain was reported by 12 (80%) participants, and periodic oral pain was reported by 4 (26.6%) participants.
Location, Intensity, Quality, and Duration of Oral Pain With Swallowing
Fifteen (47%) participants reported oral pain overall intensity with swallowing mean VAS score = 1.8 (range = 0Y10) ( Table 5 ). Seven (22%) participants reported oral pain with swallowing overall intensity mean VAS scores of more than 3. Sixteen (50%) participants reported a mean VAS score of 2.4 (range = 0Y10) for worst intensity of oral pain with swallowing within the last 24 hours; 9 (28%) participants scored more than 3. The mean sensory plus affective pain rating was 8.0 (range = 0Y84). Sensory words chosen most frequently to describe the oral pain with swallowing were sore (86.7%), burning (26.5%), aching (26.7%), and pressing (26.7%). Affective words chosen most frequently to describe oral pain with swallowing were annoying (73.3%), nagging and miserable (33.3%), and troublesome (26.7%). Twelve participants (80.0%) had continuous pain, and 4 (26.7%) participants had periodic pain with swallowing.
Oral Care Regimens
The 2 most frequently used mouth rinses prescribed by BMT unit practice were nonalcohol mouthwash with saline (n = 16) and sodium bicarbonate (n = 15). Nonalcohol mouthwash with saline was used at least 3 times daily during hospitalization by 14 participants, and 15 participants used this mouthwash at least once on data collection day. Sodium bicarbonate solution was used at least once per day during hospitalization, with 12 participants using this solution more than 3 times daily. Twelve participants used sodium bicarbonate solution on data collection day. Self-care was practiced with frequent use of lip lubricants (91%), ice chips (19%) for dry mouth, and hard candy or gum (13%) to stimulate saliva production. All but one participant used a toothbrush, mainly soft bristles, and toothpaste daily.
Medication Use
Few participants used topical anesthetics. Ulcerease (n = 3) was used 2 to 6 times for 24 hours; viscous lidocaine (n = 2) was used as needed and 6 times for 24 hours; and magic mouthwash (equal parts: Maalox, viscous lidocaine, nystatin suspension, benylin syrup) (n = 2) was used 2 to 4 times for 24 hours. Table 6 presents acetaminophen and opioids used within their duration of action during data collection. 
Anxiety and Depression

Intercorrelations Among Variables
Strength of the correlation coefficient was defined by Munro 41 as .00 to .25 = little if any; .26 to .49 = low; .50 to .69 = moderate; .70 to .89 = high; and .90 to 1.00 = very high. The correlation coefficient, equal to its effect size, was interpreted per Cohen 40 as small (r = 0.10), medium (r = 0.30), and large (r = 0.50). The critical value for the significance level of the Pearson product moment correlations based on a one-tailed test at the 0.05 level is 0.301.
Stomatitis-Related Oral Pain
Overall oral pain intensity was moderately correlated with stomatitis severity (OAG: r = 0.49, P G .01; OMI: r = 0.50, P G .01). Affective pain was highly correlated with overall oral pain intensity (r = 0.75, P G .001). Sensory pain was highly correlated with overall oral pain intensity (r = 0.75, P G .001).
Stomatitis-Related Oral Pain with Swallowing
Overall oral pain intensity was highly correlated with affective pain (r = 0.80, P G .001) and sensory pain (r = 0.79, P G .001) with swallowing. Affective pain with swallowing was highly correlated with sensory pain with swallowing (r = 0.83, P G .001). Sensory pain with swallowing was highly correlated with acute oral overall pain intensity with swallowing (r = 0.79, P G .001). Stomatitis severity (OMI) was correlated with alteration in both voice (r = 0.40, P G .05) and swallowing (r = 0.32, P G .05).
Anxiety and Depression
The correlations between overall oral pain intensity (VAS) and state anxiety (r = j0.02) and trait anxiety (r = j0.13) were extremely weak and did not reach significance. Depression was correlated with state anxiety (r = 0.42, P G .05) and moderately correlated with trait anxiety (r = 0.54, P G .01). Depression was not significantly correlated with overall oral pain intensity (VAS) (r = j0.16). State and trait anxiety were highly correlated (r = 0.85, P G 001). Trait anxiety was also correlated with alteration in voice (r = 0.33, P G .05).
Hypotheses
There was a significant, positive relationship between oral pain and stomatitis severity (r = 0.499, P G .01) after controlling for the use of analgesics. The effect size of the coefficient was medium. These was a significant, positive relationship between oral pain and alteration in swallowing (r = 0.44, P G .05) after controlling for the use of analgesics. The effect size of the coefficient was medium. There was also a significant, positive relationship between alteration in swallowing and oral pain with swallowing (r = 0.66, P G .001) after controlling for the use of analgesics. The effect size of the coefficient was large. The relationship between oral pain and state anxiety (r = 0.013, P = .947) was not statistically significant after controlling for the use of analgesics and anxiolytics. There was not a statistically significant, positive relationship between oral pain intensity and depression severity (r = j0.105, P = .588) after controlling for the use of analgesics and antidepressants.
Each increment in the proportion of variance accounted for as each variable was added to the regression was tested for significance using the F ratio (Table 7) . This test for the criterion variable was used to develop the final regression equation. The final regression equation using standard (z) scores wherein OP = overall intensity of oral pain, SP = sensory pain, and AP = affective pain was z ¶ OP = 0.459z + 0.437z The standard error of estimate for this equation was 0.927. Compared to the standard deviation of the criterion of 1.7, sensory pain and affective pain predict overall intensity of oral pain with fair to moderate accuracy.
This study had several limitations. The major limitation was the small sample size that significantly limited the statistical power of the study. In addition, the use of 2 clinical sites limits the findings to this sample. Crosssectional data collection precluded potentially observing the participant's greatest stomatitis and oral pain variance. Although self-report questionnaires and grading rules for the OMI-20 were used, the potential for experimental bias exists. components of the oral pain experience were demonstrated. Results of this study supported erythematous oral locations from previous reports. 5, 19 Interestingly, pseudomembrane/ ulceration was observed less frequently than previously described, perhaps because a combined allogeneic and autoHSCT sample was not used. Prominent erythema observed on labial and buccal mucosa, floor of the mouth, and soft palate showed sensitivity of nonkeratinized anatomical areas to chemotherapy effects 5, 19 and supported the need for frequent, consistent inspection of these sites by nurses. Although low mean OMI and OAG scores were reported for stomatitis and alterations in voice and swallowing (OAG), wide ranges indicated that some participants did experience moderate to severe stomatitis and moderate alterations in swallowing and voice. Oral pain was described by participants as a multidimensional experience. Although the significant positive relationship seen between oral pain intensity and stomatitis severity supports previous reports, 20 this oral pain is more complex than a direct correlation with the amount of tissue damage. 11 Although low mean scores for oral pain were reported, the wide range of pain VAS scores indicated that some participants had moderate to severe oral pain intensity. Mild to moderate sensory oral pain intensity was reported. Mild affective oral pain intensity was reported. Clinically significant findings included 5 participants reporting oral pain intensity ratings of more than 3, a total of 7 participants experiencing worst oral pain intensity ratings within the last 24 hours of more than 3, and 12 participants having continuous oral pain for 3 to 10 days. Continuous pain places patients at risk for fatigue, symptom distress, and unintended biological effects. Oral pain ratings of more than 3 reported by patients using either a fentanyl transdermal patch or receiving fentanyl via continuous infusion demonstrates the importance of frequent pain assessment to determine effectiveness of both opioid type and titration of opioid dose to this dynamic oral pain experience.
The wide range of pain VAS scores with swallowing indicated that some participants had moderate to severe oral pain intensity, mild to severe sensory oral pain intensity, and moderate affective oral pain intensity with swallowing. Clinically significant findings included pain with swallowing intensity ratings of more than 3 (n = 7), worst oral pain within last 24 hours ratings of more than 3 (n = 10), and continuous oral pain for 2 to 7 days (n = 12). Assessing pain on swallowing is critical to manage this important symptom that is related to alterations in nutritional intake often seen in the HSCT setting.
The findings that a subset of participants experienced uncontrolled oropharyngeal pain despite the use of clinical site specific pain management algorithms reinforces the need for more individualized pain assessments and interventions to manage pain and mucosal injury. Valid and reliable assessment tools are key components of stomatitis-related oropharyngeal pain assessment, and the OAG, OMI, and POM demonstrated clinical utility in this sample. The potential communication challenges related to altered voice from edematous and painful oral mucous membranes require the use of appropriate pain assessment tools such as the POM.
The lack of a significant positive relationship between oral pain and state anxiety and depression may be related to having a limited statistical power of the study and to assessing anxiety in a sample that did not experience high morbidity pre-HSCT. Oral sensory and affective pain intensity most accurately predicted oral pain overall intensity, and participants were able to discriminate between these 2 dimensions of the oropharyngeal pain experience. Assessing multiple dimensions of stomatitis-related oropharyngeal pain would yield a more comprehensive understanding of this pain experience than measuring only the pain overall intensity.
Although this study focused on patients with breast cancer receiving autoHSCT, the research design is appropriate to examine stomatitis-related oral pain in diverse oncology populations. Future research is needed to explore risk factors for and factors that affect perception and response to stomatitis-related oropharyngeal pain, 42 individual patient response to opioid treatment, and effectiveness of pain management algorithms for multiple dimensions of this oropharyneal pain. This clinical research may also be enhanced through the use of interview techniques to assess subjective tolerance of symptoms. 43 
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